Drug Trial Radar · NCT07406360
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,209
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Feb 28, 2028
Study completion Jul 20, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 months, up to 6 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).
Conditions
- Measles
- Measles-Mumps-Rubella+Chickenpox Vaccine
Interventions
MMRVNSBiological
One dose of MMRVNS administered intramuscularly.
MMRVBiological
One dose of MMRV administered intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroresponse of Immunoglobulin G (IgG) concentrations against measlesTime frame: At Day 43
- Seroresponse of IgG concentrations against mumpsTime frame: At Day 43
- Seroresponse of IgG concentrations against rubellaTime frame: At Day 43
- Seroresponse of IgG concentrations against Varicella zoster virus (VZV)Time frame: At Day 43
- IgG concentrations against measlesTime frame: At Day 43
- IgG concentrations against mumpsTime frame: At Day 43
- IgG concentrations against rubellaTime frame: At Day 43
- IgG concentrations against VZVTime frame: At Day 43
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama · Recruiting
GSK Investigational Site
Walnut Creek, California · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Atlanta, Georgia · Recruiting
GSK Investigational Site
Chicago, Illinois · Recruiting
GSK Investigational Site
Farmington Hills, Michigan · Recruiting
GSK Investigational Site
Dayton, Ohio · Recruiting
GSK Investigational Site
Simpsonville, South Carolina · Recruiting
GSK Investigational Site
Spartanburg, South Carolina · Recruiting
GSK Investigational Site
Frisco, Texas · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Port Lavaca, Texas · Recruiting
GSK Investigational Site
Richmond, Texas · Recruiting
GSK Investigational Site
Provo, Utah · Recruiting
GSK Investigational Site
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.